Share Name Share Symbol Market Type Share ISIN Share Description
Bioventix LSE:BVXP London Ordinary Share GB00B4QVDF07 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +10.00p +0.38% 2,610.00p 2,570.00p 2,650.00p 2,610.00p 2,600.00p 2,600.00p 6,844 11:20:37
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 7.2 5.8 96.4 27.1 133.07

Bioventix Share Discussion Threads

Showing 776 to 797 of 800 messages
Chat Pages: 32  31  30  29  28  27  26  25  24  23  22  21  Older
DateSubjectAuthorDiscuss
18/4/2018
10:37
At the results presentation, Peter had said that Siemens were excited about the potential for high sensitivity Troponin to be used as a more regular test of cardiac disease monitoring/progression beyond just A&E. This research would appear to support this view. Http://jaha.ahajournals.org/content/7/5/e007914 This, I believe, was done using the Abbott hsTnI test. "Higher hsTnI levels are associated with the underlying burden of coronary atherosclerosis, more rapid progression of CAD [coronary artery disease], and higher risk of all‐cause mortality and incident cardiovascular events." The clinical implications are interesting: 1) "High‐sensitivity cardiac troponin I is potentially a surrogate biomarker to monitor therapeutic responses in patients with coronary artery disease" and 2) "Whether interventions aimed at reducing its levels are associated with improved outcomes requires further investigation"
gsbmba99
29/3/2018
15:29
See what a difference a header update makes :-)
stepone68
29/3/2018
14:35
Happy reading like the share price again!
igbertsponk
28/3/2018
23:18
Not a problem, it had been neglected... Last two half years now added-in, and makes for happy reading.
strollingmolby
28/3/2018
21:17
Thanks, sorry, didn't mean to sound like I was nagging! Just that I like the '6 month segment' breakdown..
stepone68
28/3/2018
14:56
stepone, yes I should get to it in the coming days...
strollingmolby
27/3/2018
12:47
Is nobody updating the header here any more?
stepone68
27/3/2018
11:35
Soon be back to its deserved £30 at this rate!
igbertsponk
26/3/2018
17:57
A somewhat useful article post the FDA's Nov 17 Troponin meeting: Https://www.aacc.org/publications/cln/articles/2018/march/the-future-of-cardiac-troponin-testing Interesting to see that Singulex say they filed for approval in November (but haven't been cleared and are now behind the normal 3 month clearance curve). So, FDA not halting applications for approval but also not issuing any clarification and not clearing any applications.
gsbmba99
26/3/2018
16:10
Not in relation to something with a near term impact but, from the FY17 results: "On a longer term perspective, we continue to work with our partners in Norway on the secretoneurin (CardiNor & heart diagnostics) and amyloid projects (Pre Diagnostics & dementia). We have made exciting antibodies to contribute towards the scientific development of these projects and we look forward to developing the science of these long term projects over the coming years."
gsbmba99
26/3/2018
16:00
"commercial development of this exciting new product would not gear up until calendar year 2018" Not sure I can ever remember such a positive word as "exciting" in a BVXP announcement. I suspect it means that we're in for a few more years of bumper performance.
igbertsponk
26/3/2018
15:48
The £770k relates to the period "1 July 2014 to 30 June 2017". So, 3 financial years but it probably has growth within that period so it could be something like £200k, £250k and £300k for instance. I haven't seen anything that states whether the royalty understatement relates to a royalty stream for which there is a continuing revenue expectation. It would be helpful to know that. If it doesn't relate to an expired revenue stream it's a nice recurring revenue uplift assuming the client can now calculate it correctly.
gsbmba99
26/3/2018
15:40
The 770k was over 4 years, so an extra 200k per year, say, missed off the previous 4 years accounts, and, assuming Siemens have improved their processes so that they don't miss these in the future, should have a positive impact going forward? StepOne
stepone68
26/3/2018
12:21
I'm guessing the change from 86 to 99 basically means they've added the 770k backdated royalties.
stepone68
26/3/2018
12:16
Re: Finncap for those who don't have access. 2018 eps forecast raised from 85.9p to 99.2p (H2 Troponin revenue forecast reduced to £500k from £750k). Total 2018 FY dividend forecast is 64p (up from 61p) which clearly leaves room for plenty of upside, given today's half-year divi declaration.
crazycoops
26/3/2018
12:08
I should add, it is titled, "What a nice surprise!" - quite!
crazycoops
26/3/2018
12:06
The Finncap note is in Research Tree, Leon
crazycoops
26/3/2018
12:01
Annoying I didn't add. Should have remembered that this company never disappoints.
igbertsponk
26/3/2018
10:29
Thanks Leon One can only hope they have gone to others and queried the royalty calculation
nfs
26/3/2018
10:13
Was worried these results might disappoint after recent share price weakness but really pleased with these. Looks like we will get another special div with full year results as well with cash held continuing to rise. Will continue to hold.
whilstev
26/3/2018
07:22
Great results. Lost revenue more than made up for and a nice £0.7m of backdated royalties. Hopefully the price will recover somewhat. Edited to say "Good to see the backdated royalties not just accounted for, but received in cash (post y/e) too".
igbertsponk
18/3/2018
09:22
Thanks valustar1. Good to know a date.
lauders
Chat Pages: 32  31  30  29  28  27  26  25  24  23  22  21  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20180421 23:04:51